2014
DOI: 10.1007/s12609-014-0163-y
|View full text |Cite
|
Sign up to set email alerts
|

Ki67 as a Biomarker of Prognosis and Prediction: Is it Ready for Use in Routine Pathology Practice?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 35 publications
0
3
0
Order By: Relevance
“…There have been international standardization efforts to reduce observer variability in PI measurement, but many challenges remain (Khademi, 2013). Points of discussion include variability in manually counted cells (Khademi, 2013), the selection of appropriate cut-off thresholds for protein detection (Albarracin and Dhamne, 2014), the number of high power fields to evaluate (Harris et al, 2016), and the PI ranges that correlate to prognosis, i.e., low (<10%), intermediate (11-30%), and high (>30%) levels of proliferation activity (Khademi, 2013). The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology have concluded that Ki67 would be a useful clinical tool if it was standardized (Dowsett et al, 2011;Senkus et al, 2015).…”
Section: Introductionmentioning
confidence: 99%
“…There have been international standardization efforts to reduce observer variability in PI measurement, but many challenges remain (Khademi, 2013). Points of discussion include variability in manually counted cells (Khademi, 2013), the selection of appropriate cut-off thresholds for protein detection (Albarracin and Dhamne, 2014), the number of high power fields to evaluate (Harris et al, 2016), and the PI ranges that correlate to prognosis, i.e., low (<10%), intermediate (11-30%), and high (>30%) levels of proliferation activity (Khademi, 2013). The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology have concluded that Ki67 would be a useful clinical tool if it was standardized (Dowsett et al, 2011;Senkus et al, 2015).…”
Section: Introductionmentioning
confidence: 99%
“…There have been international standardization efforts to reduce observer variability in PI measurement, but many challenges remain (Khademi, 2013). Points of discussion include variability in manually counted cells (Khademi, 2013), the selection of appropriate cut-off thresholds for protein detection (Albarracin and Dhamne, 2014), the number of high power fields to evaluate (Harris et al, 2016), and the PI ranges that correlate to prognosis, i.e., low (<10%), intermediate (11-30%), and high (>30%) levels of proliferation activity (Khademi, 2013). The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology have concluded that Ki67 would be a useful clinical tool if it was standardized (Dowsett et al, 2011;Senkus et al, 2015).…”
Section: Introductionmentioning
confidence: 99%
“…There have been international standardization efforts to reduce observer variability in PI measurement, but many challenges remain (Khademi, 2013). Points of discussion include variability in manually counted cells (Khademi, 2013), the selection of appropriate cut-off thresholds for protein detection (Albarracin and Dhamne, 2014), the number of high power fields to evaluate (Harris et al, 2016), and the PI ranges that correlate to prognosis, i.e., low (<10%), intermediate (11–30%), and high (>30%) levels of proliferation activity (Khademi, 2013). The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology have concluded that Ki67 would be a useful clinical tool if it was standardized (Dowsett et al, 2011; Senkus et al, 2015).…”
Section: Introductionmentioning
confidence: 99%